Loading publications…
The last 5 uploaded publications
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial
Patrick W. Serruys, Bernard Chevalier, Dariusz Dudek, Ángel Cequier, Didier Carrié, Andrés Íñiguez, Marcello Dominici, René J. van der Schaaf, Michael Haude, Luc Wasungu, Susan Veldhof, Lei Peng, Peter Stæhr, Maik J. Grundeken, Yuki Ishibashi, Héctor M. García‐García, Yoshinobu Onuma (2014). A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. The Lancet, 385(9962), pp. 43-54, DOI: 10.1016/s0140-6736(14)61455-0.
Article146 days agoEvaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis
Patrick W. Serruys, Yoshinobu Onuma, Dariusz Dudek, Pieter C. Smits, Jacques Koolen, Bernard Chevalier, Bernard De Bruyne, Leif Thuesen, Dougal McClean, Robert‐Jan van Geuns, Stephan Windecker, Robert Whitbourn, Ian T. Meredith, Cécile Dorange, Susan Veldhof, Karine Miquel Hebert, Krishnankutty Sudhir, Héctor M. García‐García, John A. Ormiston (2011). Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis. Journal of the American College of Cardiology, 58(15), pp. 1578-1588, DOI: 10.1016/j.jacc.2011.05.050.
Article146 days agoComparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial
Patrick W. Serruys, Bernard Chevalier, Yohei Sotomi, Ángel Cequier, Didier Carrié, Jan J. Piek, Ad J. van Boven, Marcello Dominici, Dariusz Dudek, Dougal McClean, Steffen Helqvist, Michael Haude, Sebastian Reith, Manuel Almeida, Gianluca Campo, Andrés Íñiguez, Manel Sabaté, Stephan Windecker, Yoshinobu Onuma (2016). Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. The Lancet, 388(10059), pp. 2479-2491, DOI: 10.1016/s0140-6736(16)32050-5.
Article146 days agoEvaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis
Patrick W. Serruys, Yoshinobu Onuma, John A. Ormiston, Bernard De Bruyne, Evelyn Regar, Dariusz Dudek, Leif Thuesen, Pieter C. Smits, Bernard Chevalier, Dougal McClean, Jacques Koolen, Stephan Windecker, Robert Whitbourn, Ian T. Meredith, Cécile Dorange, Susan Veldhof, Karine Miquel‐Hébert, Richard Rapoza, Héctor M. García‐García (2010). Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis. Circulation, 122(22), pp. 2301-2312, DOI: 10.1161/circulationaha.110.970772.
Article146 days agoDynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months
Patrick W. Serruys, Yoshinobu Onuma, Héctor M. García‐García, Takashi Muramatsu, Robert‐Jan van Geuns, Bernard De Bruyne, Dariusz Dudek, Leif Thuesen, Pieter C. Smits, Bernard Chevalier, Dougal McClean, Jacques Koolen, Stephan Windecker, Robert Whitbourn, Ian T. Meredith, Cécile Dorange, Susan Veldhof, Karine Miquel Hebert, Richard Rapoza, John A. Ormiston (2014). Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention, 9(11), pp. 1271-1284, DOI: 10.4244/eijv9i11a217.
Article146 days ago